(thirdQuint)A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer.

 This is a phase II clinical trial.

 Phase II clinical trials test the safety and effectiveness of an investigational intervention to learn whether the intervention works in treating a specific disease.

 "Investigational" means that the intervention is being studied.

 The FDA (the U.

S.

 Food and Drug Administration) has approved regorafenib as a treatment for metastatic colorectal cancer and locally advanced, unresectable or metastatic gastrointestinal stromal tumor.

 Regorafenib has not been approved for treatment against thyroid cancer.

 Regorafenib is an oral anti-tumor agent that blocks activity of a specific kind of protein involved in normal cellular functions and in pathologic processes such as tumor formation and maintenance.

.

 A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer@highlight

This research study is studying a targeted therapy as a possible treatment for thyroid cancer.

 A targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific types of cancer cells with less harm to normal cells.

 - The name of the study intervention involved in this study is regorafenib.

